Compare Immunovant Inc. Common Stock (IMVT) vs Nu Holdings Ltd (NU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs Nu Holdings Ltd — how do they compare? Immunovant Inc. Common Stock trades at $30.01 (market cap $6.25B), while Nu Holdings Ltd trades at $15.45 (market cap $74.30B). The key difference: Nu Holdings Ltd is far larger — about 11.9× Immunovant Inc. Common Stock's market cap, and Nu Holdings Ltd is more actively traded (80,294,805 versus 1,755,411). Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and Nu Holdings Ltd for 53 Days on average.
| IMVT | NU | |
|---|---|---|
Market Cap | $6.25B | $74.30B |
Volume | 1,755,411 | 80,294,805 |
Sector | Health | Financials |
52-Week High | $44.96 | $18.76 |
52-Week Low | $17.03 | $11.60 |
Typical Hold Time | 0 Days | 53 Days |
Enterprise Value | $5.35B | $96.91B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
NU Holdings (NU) trades at $15.58, down 0.51% on the day, as the Brazilian digital bank navigates market volatility. The stock shows strong fundamental momentum with revenue growing from $3.0B in 2022 to $10.6B in 2025 and net income turning positive to $2.9B. Technical indicators are mixed with a bullish moving average signal but overbought RSI conditions. Recent news highlights acquisition speculation and Goldman Sachs' bullish $19 price target.
NU presents a compelling growth story with expanding profitability and analyst support, though risks include credit concentration and acquisition uncertainty. The stock trades near consensus targets with 57% buy ratings, suggesting moderate upside potential if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About Nu Holdings Ltd
Nu Holdings Ltd is engaged in providing digital banking services. It offers several financial services such as Credit cards, Personal Account, Investments, Personal Loans, Insurance, Mobile payments, Business Account, and Rewards.
Read more on NU →
